Abstract
Purpose To evaluate the efficacy and safety of the combination of carboplatin plus paclitaxel in patients with advanced, metastatic and recurrent endometrial cancer. Methods Medical records were retrospectively reviewed to identify endometrial cancer patients treated in the Gynecologic Cancer Program of the Cleveland Clinic with carboplatin/paclitaxel who had both a histologic diagnosis of endometrial adenocarcinoma and either measurable (CT scan, physical examination) or evaluable (CA-125 criteria) disease. Results From 1994 to 2003, 22 individuals (median age 65 years) meeting the above noted criteria received a total of 23 courses of carboplatin (AUC 4–6)/paclitaxel (135–175 mg/m2) administered on a 21-day schedule (median six cycles/patient). The overall response rate was 87% (20/23). The most common toxicity was hematologic. Five patients required dose reductions due to excessive toxicity (three hematologic, one gastrointestinal, one fatigue). There were no treatment related deaths. With a median follow-up of 42 months, 13 patients have died of progressive cancer, while four currently have no evidence of disease at the time of last follow-up. Conclusions The combination of carboplatin plus paclitaxel demonstrates substantial biological activity in endometrial adenocarcinoma. The safety and efficacy of this regimen makes it an attractive option for first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ball HG, Blessing JA et al (1996) A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 62(2):278–281
Barakat RR, Grigsby PW et al (2000) Corpus: epithelial tumors. In: Hoskins WJ Principles and practice of gynecologic oncology. Lippincott Williams and Wilkins, Philadelphia, pp 919–959
Barrett RJ, Blessing JA et al (1993) Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 16(6):494–496
Blessing JA (1990) Design analysis and interpretation of chemotherapy trials in gynecologic cancer. In: Deppe G Chemotherapy of gynecologic cancer. Alan R. Liss Inc, Scientific and Medical Publications, New York, pp 63–97
Burke TW, Munkarah A et al (1993) Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecol Oncol 51(3):397–400
Burke TW, Stringer CA et al (1991) Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol 40(3):264–267
Dimopoulos MA, Papadimitriou CA et al (2000) Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. Gynecol Oncol 78(1):52–57
du Bois A, Luck HJ et al (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95(17):1320–1329
Duk JM, Aalders JG et al (1986) CA 125: a useful marker in endometrial carcinoma. Am J Obstet Gynecol 155(5):1097–1102
Fleming GF, Fowler JM et al (2001) Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study. J Clin Oncol 19(4):1021–1029
Hoskins PJ, Swenerton KD et al (2001) Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 19(20):4048–4053
Le TD, Yamada SD et al (1999) Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with taxol and carboplatin. Gynecol Oncol 73(3):461–463
Lincoln S, Blessing JA et al (2003) Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 88(3):277–281
Markman M, Kennedy A et al (2000) Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 78(3Pt1):369–372
Neijt JP, du Bois A (1999) Paclitaxel/carboplatin for the initial treatment of advanced ovarian cancer. Semin Oncol 26(1Suppl2):78–83
Price FV, Edwards RP et al (1997) A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report. Semin Oncol 24(5Suppl15):S15-78–S15-S82
Skarlos DV, Aravantinos G et al (1997) Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study. Semin Oncol 24(5Suppl15):S15-57–S15-61
Thigpen JT, Blessing JA et al (1994) A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 12(7):1408–1414
Vasuratna A, Kudelka AP et al (1998) Prolonged remission of endometrial cancer with paclitaxel and carboplatin. Anticancer Drugs 9(3):283–285
Weber B, Mayer F et al (2003) What is the best chemotherapy regimen in recurrent or advanced endometrial carcinoma? Preliminary results. ProcASCO 22:1819
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Michener, C.M., Peterson, G., Kulp, B. et al. Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma. J Cancer Res Clin Oncol 131, 581–584 (2005). https://doi.org/10.1007/s00432-005-0676-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-005-0676-x